Fortress Biotech, Inc. Debt Conversion, Converted Instrument, Amount
Fortress Biotech, Inc. (FBIO) reported Debt Conversion, Converted Instrument, Amount of $0 for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-11-15.
Discontinued › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2022-03-28
- Fortress Biotech, Inc. debt conversion, converted instrument, amount for the quarter ending 2020-12-31 was $0.00.
- Fortress Biotech, Inc. debt conversion, converted instrument, amount for the quarter ending 2019-12-31 was $0.00.
- Fortress Biotech, Inc. debt conversion, converted instrument, amount for the quarter ending 2017-03-31 was $206.00K.
- Fortress Biotech, Inc. debt conversion, converted instrument, amount for the quarter ending 2016-12-31 was $634.00K, a 456.14% increase year-over-year.
- Fortress Biotech, Inc. debt conversion, converted instrument, amount for fiscal 2020 was $4.42M.
- Fortress Biotech, Inc. debt conversion, converted instrument, amount for fiscal 2019 was $0.00.
- Fortress Biotech, Inc. debt conversion, converted instrument, amount for fiscal 2016 was $634.00K, a 456.14% increase from fiscal 2015.
- Fortress Biotech, Inc. debt conversion, converted instrument, amount for fiscal 2015 was $114.00K.
| Period end | Debt Conversion, Converted Instrument, Amount 3 month | Debt Conversion, Converted Instrument, Amount 6 month | Debt Conversion, Converted Instrument, Amount 9 month | Debt Conversion, Converted Instrument, Amount 9 month as first filed | Debt Conversion, Converted Instrument, Amount 12 month |
|---|---|---|---|---|---|
| 2021-09-30 | $0.00 10-Q · filed 2021-11-15 | ||||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $4.42M 10-K · filed 2022-03-28 | |||
| 2020-09-30 | $4.42M 10-Q · filed 2021-11-15 | ||||
| 2019-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2021-04-09 | $0.00 10-K/A · filed 2021-04-09 | |||
| 2019-09-30 | $0.00 10-Q · filed 2020-11-09 | ||||
| 2017-09-30 | $314.00K 10-Q · filed 2017-11-09 | ||||
| 2017-03-31 | $206.00K 10-Q · filed 2017-05-10 | $840.00K derived: sum of 2 quarters · filed 2017-05-10 | $741.00K derived: sum of 3 quarters · filed 2017-11-09 | $840.00K derived: sum of 4 quarters · filed 2017-11-09 | |
| 2016-12-31 | $634.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $535.00K derived: sum of 2 quarters · filed 2017-11-09 | $634.00K derived: sum of 3 quarters · filed 2017-11-09 | $634.00K 10-K · filed 2017-03-16 | |
| 2016-09-30 | -$99.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $0.00 derived: sum of 2 quarters · filed 2017-11-09 | $0.00 10-Q · filed 2017-11-09 | $634.00K 10-Q · filed 2016-11-09 | $114.00K derived: sum of 4 quarters · filed 2017-11-09 |
| 2016-06-30 | $99.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $99.00K 10-Q · filed 2016-08-09 | $213.00K derived: sum of 3 quarters · filed 2017-05-10 | $213.00K derived: sum of 4 quarters · filed 2017-05-10 | |
| 2016-03-31 | $0.00 10-Q · filed 2017-05-10 | $114.00K derived: sum of 2 quarters · filed 2017-05-10 | $114.00K derived: sum of 3 quarters · filed 2017-05-10 | ||
| 2015-12-31 | $114.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $114.00K derived: sum of 2 quarters · filed 2017-03-16 | $114.00K 10-K · filed 2017-03-16 | ||
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $0.00 10-Q · filed 2016-11-09 | |||
| 2015-06-30 | $0.00 10-Q · filed 2016-08-09 | ||||
| 2014-12-31 | $0.00 10-K · filed 2017-03-16 | ||||
| 2013-12-31 | $0.00 10-K · filed 2016-03-15 | ||||
| 2012-12-31 | $323.00K 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |